Shionogi

Live  

Shionogi is a Japanese pharmaceutical company that was founded in 1878. It is headquartered in Osaka, Japan and has a presence in over 50 countries worldwide. The company's main focus is on the research, development, and commercialization of pharmaceutical products in various therapeutic areas, including infectious diseases, oncology, and cardiovascular diseases.
Shionogi is known for its innovative research and development programs, with a strong emphasis on tackling global health challenges. Some of the company's most notable research achievements include the development of new treatments for HIV/AIDS, tuberculosis, and influenza.
In addition to its pharmaceutical business, Shionogi also has a presence in the consumer health and microbiome businesses. It has partnerships and collaborations with other pharmaceutical companies, research institutions, and universities to develop new treatments and technologies.
The company's mission is to provide innovative medicines and solutions to improve the health and wellbeing of people worldwide. It is committed to responsible and ethical business practices, as well as sustainability and environmental conservation.
Currently, Shionogi is focused on expanding its global presence and advancing its pipeline of drug candidates to address unmet medical needs. It also continues to invest in research and development, with the goal of bringing new and improved treatments to patients in need.

Shionogi is a company that works with medicine, kind of like superheroes who help people feel better when they’re sick. They create special products called drugs that help treat diseases and infections, like when you have a cold or a more serious problem.
Shionogi makes money by selling these medicines to hospitals and pharmacies. When people go to the doctor and need medicine to help them heal, the doctor may prescribe Shionogi’s products. The company also sells their medicines to other countries, which helps them make even more money.
One reason Shionogi is successful is because they focus on making really good and effective medicines. They spend a lot of time and effort researching and testing their products to make sure they work well and are safe for people to use. This means that doctors and patients trust their medicines.
In the future, Shionogi is likely to continue being successful because they are always working on new medicines and improving existing ones. They keep an eye on new diseases and problems that people face, so they can create solutions when needed. Additionally, as more people around the world need healthcare, companies like Shionogi that provide important medicines will remain important and can continue to thrive.

MS4gTG9uZy BIaXN0b3J5 IGFuZCBTdH JvbmcgUmVw dXRhdGlvbj ogU2hpb25v Z2kgaGFzIG EgbG9uZyBo aXN0b3J5IG RhdGluZyBi YWNrIHRvID E4NzguIEl0 IGlzIGtub3 duIGZvciBp dHMgc3Ryb2 5nIHRyYWNr IHJlY29yZC BvZiBkZXZl bG9waW5nIG FuZCBtYXJr ZXRpbmcgaW 5ub3ZhdGl2 ZSBtZWRpY2 luZXMgaW4g SmFwYW4gYW 5kIGdsb2Jh bGx5Ljxicj 4yLiBGb2N1 cyBvbiBJbm ZlY3Rpb3Vz IERpc2Vhc2 VzOiBTaGlv bm9naSBpcy Bjb21taXR0 ZWQgdG8gZG V2ZWxvcGlu ZyB0cmVhdG 1lbnRzIGZv ciBpbmZlY3 Rpb3VzIGRp c2Vhc2VzIH N1Y2ggYXMg SElWLCBpbm ZsdWVuemEs IGFuZCBhbn RpYmlvdGlj LXJlc2lzdG FudCBpbmZl Y3Rpb25zLC B3aGljaCBh cmUgb2Z0ZW 4gbmVnbGVj dGVkIGJ5IG 90aGVyIHBo YXJtYWNldX RpY2FsIGNv bXBhbmllcy 48YnI+My4g RGl2ZXJzaW ZpZWQgUG9y dGZvbGlvOi BTaGlvbm9n aSBoYXMgYS BkaXZlcnNp ZmllZCBwb3 J0Zm9saW8s IHdpdGggcH JvZHVjdHMg cmFuZ2luZy Bmcm9tIHBy ZXNjcmlwdG lvbiBkcnVn cyB0byBvdm VyLXRoZS1j b3VudGVyIG 1lZGljaW5l cywgZGlhZ2 5vc3RpY3Ms IGFuZCBtZW RpY2FsIGRl dmljZXMuPG JyPjQuIElu dGVybmF0aW 9uYWwgUHJl c2VuY2U6IF NoaW9ub2dp IGhhcyBhIH N0cm9uZyBw cmVzZW5jZS BpbiB0aGUg aW50ZXJuYX Rpb25hbCBt YXJrZXQsIH dpdGggb3Bl cmF0aW9ucy BpbiBOb3J0 aCBBbWVyaW NhLCBFdXJv cGUsIGFuZC BBc2lhLiBU aGlzIGdsb2 JhbCByZWFj aCBhbGxvd3 MgdGhlIGNv bXBhbnkgdG 8gYWNjZXNz IG5ldyBtYX JrZXRzIGFu ZCBjb2xsYW JvcmF0ZSB3 aXRoIGludG VybmF0aW9u YWwgcGFydG 5lcnMuPGJy PjUuIFJlc2 VhcmNoIGFu ZCBEZXZlbG 9wbWVudDog VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudCB0byBi cmluZyBuZX cgYW5kIGlu bm92YXRpdm UgbWVkaWNp bmVzIHRvIG 1hcmtldC4g U2hpb25vZ2 kncyBSJkQg ZWZmb3J0cy BoYXZlIGxl ZCB0byB0aG UgZGV2ZWxv cG1lbnQgb2 YgYnJlYWt0 aHJvdWdoIG RydWdzIGlu IHZhcmlvdX MgdGhlcmFw ZXV0aWMgYX JlYXMuPGJy PjYuIFN0cm 9uZyBQaXBl bGluZTogU2 hpb25vZ2kg aGFzIGEgcm 9idXN0IHBp cGVsaW5lIG 9mIHBvdGVu dGlhbCBuZX cgbWVkaWNh dGlvbnMsIH dpdGggb3Zl ciA0MCBwcm 9kdWN0cyBp biBkZXZlbG 9wbWVudC4g VGhpcyBlbn N1cmVzIGEg c3RlYWR5IH N0cmVhbSBv ZiBuZXcgcH JvZHVjdHMg dG8gZHJpdm UgZ3Jvd3Ro IGluIHRoZS BmdXR1cmUu PGJyPjcuIE NvcnBvcmF0 ZSBTb2NpYW wgUmVzcG9u c2liaWxpdH k6IFNoaW9u b2dpIGlzIG NvbW1pdHRl ZCB0byBiZW luZyBhIHNv Y2lhbGx5IH Jlc3BvbnNp YmxlIGNvbX BhbnksIGZv Y3VzaW5nIG 9uIGV0aGlj YWwgYW5kIH Jlc3BvbnNp YmxlIGJ1c2 luZXNzIHBy YWN0aWNlcy wgZW52aXJv bm1lbnRhbC BzdXN0YWlu YWJpbGl0eS wgYW5kIHN1 cHBvcnRpbm cgdGhlIGNv bW11bml0aW VzIGluIHdo aWNoIGl0IG 9wZXJhdGVz Ljxicj44Li BTdHJvbmcg RmluYW5jaW FsIFBlcmZv cm1hbmNlOi BTaGlvbm9n aSBoYXMgYS BzdHJvbmcg ZmluYW5jaW FsIHRyYWNr IHJlY29yZC wgY29uc2lz dGVudGx5IG RlbGl2ZXJp bmcgcHJvZm l0cyBhbmQg aW5jcmVhc2 VkIHJldmVu dWUgb3Zlci B0aGUgeWVh cnMuIFRoaX MgZmluYW5j aWFsIHN0YW JpbGl0eSBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gY2 9udGludWUg aW52ZXN0aW 5nIGluIHJl c2VhcmNoIG FuZCBkZXZl bG9wbWVudC BhbmQgZXhw YW5kaW5nIG l0cyBnbG9i YWwgcHJlc2 VuY2UuPGJy PjkuIEF3YX JkLVdpbm5p bmcgSW5ub3 ZhdGlvbnM6 IFNoaW9ub2 dpJ3MgY29t bWl0bWVudC B0byBpbm5v dmF0aW9uIG hhcyBiZWVu IHJlY29nbm l6ZWQgYnkg dmFyaW91cy BwcmVzdGln aW91cyBhd2 FyZHMsIHN1 Y2ggYXMgdG hlIE5pa2tl aSBTdXBlcm lvciBQcm9k dWN0cyBhbm QgU2Vydmlj ZXMgQXdhcm QgYW5kIHRo ZSBKYXBhbi BCaW9pbmR1 c3RyeSBBc3 NvY2lhdGlv biBBd2FyZC 48YnI+MTAu IEVtcGxveW VlIFNhdGlz ZmFjdGlvbj ogU2hpb25v Z2kgaXMga2 5vd24gZm9y IGl0cyBwb3 NpdGl2ZSB3 b3JrIGN1bH R1cmUgYW5k IGVtcGxveW VlIHNhdGlz ZmFjdGlvbi 4gVGhlIGNv bXBhbnkgaG FzIGJlZW4g cmVjb2duaX plZCBhcyBv bmUgb2YgdG hlIGJlc3Qg cGxhY2VzIH RvIHdvcmsg aW4gSmFwYW 4gYW5kIGds b2JhbGx5LC Bwcm9tb3Rp bmcgZGl2ZX JzaXR5LCBp bmNsdXNpb2 4sIGFuZCBl bXBsb3llZS B3ZWxsLWJl aW5nLg==

VGhlIFNoaW 9ub2dpIGNv bXBhbnkgaX MgYSBKYXBh bmVzZSBwaG FybWFjZXV0 aWNhbCBjb2 1wYW55LiBJ dHMgYnVzaW 5lc3MgbW9k ZWwgcmV2b2 x2ZXMgYXJv dW5kIHJlc2 VhcmNoaW5n LCBkZXZlbG 9waW5nLCBt YW51ZmFjdH VyaW5nLCBh bmQgbWFya2 V0aW5nIHBy ZXNjcmlwdG lvbiBhbmQg b3Zlci10aG UtY291bnRl ciBtZWRpY2 luZXMuIEl0 cyBmb2N1cy BpcyBwcmlt YXJpbHkgb2 4gdHJlYXRt ZW50cyBmb3 IgaW5mZWN0 aW91cyBkaX NlYXNlcywg cGFpbiwgYW 5kIGNhbmNl ci4gPGJyPl RoZSBjb21w YW55IGFsc2 8gaGFzIGEg cmVzZWFyY2 ggYW5kIGRl dmVsb3BtZW 50IHBpcGVs aW5lIGZvci BuZXcgZHJ1 Z3MgYW5kIG NvbnRpbnVv dXNseSBpbn Zlc3RzIGlu IHBhcnRuZX JzaGlwcyBh bmQgY29sbG Fib3JhdGlv bnMgdG8gZn VydGhlciBl eHBhbmQgaX RzIHByb2R1 Y3QgcG9ydG ZvbGlvLiA8 YnI+QWRkaX Rpb25hbGx5 LCBTaGlvbm 9naSBoYXMg YSBnbG9iYW wgcHJlc2Vu Y2UsIHdpdG ggb3BlcmF0 aW9ucyBpbi BBc2lhLCBF dXJvcGUsIG FuZCB0aGUg VW5pdGVkIF N0YXRlcywg c2VsbGluZy BpdHMgcHJv ZHVjdHMgaW 4gbW9yZSB0 aGFuIDkwIG NvdW50cmll cy4gPGJyPk Z1cnRoZXJt b3JlLCB0aG UgY29tcGFu eSBhbHNvIG hhcyBhIHN0 cm9uZyBjb2 1taXRtZW50 IHRvIGNvcn BvcmF0ZSBz b2NpYWwgcm VzcG9uc2li aWxpdHksIG luY2x1ZGlu ZyBlZmZvcn RzIHRvIHJl ZHVjZSBpdH MgZW52aXJv bm1lbnRhbC BpbXBhY3Qg YW5kIHByb3 ZpZGUgYWNj ZXNzIHRvIG 1lZGljaW5l IGluIHVuZG Vyc2VydmVk IGNvbW11bm l0aWVzLiA8 YnI+SW4gc3 VtbWFyeSwg U2hpb25vZ2 kncyBidXNp bmVzcyBtb2 RlbCBpbnZv bHZlcyB0aG UgZGV2ZWxv cG1lbnQgYW 5kIHByb2R1 Y3Rpb24gb2 YgaW5ub3Zh dGl2ZSBwaG FybWFjZXV0 aWNhbCBwcm 9kdWN0cywg c3RyYXRlZ2 ljIHBhcnRu ZXJzaGlwcy BhbmQgY29s bGFib3JhdG lvbnMsIGFu ZCBhIGZvY3 VzIG9uIHNv Y2lhbCByZX Nwb25zaWJp bGl0eS4=

AI does present potential challenges and opportunities for Shionogi and companies in the pharmaceutical and healthcare sectors.
1. Substitution: AI can develop new drugs or therapies more quickly and at lower costs than traditional methods. If competitors effectively utilize AI for drug discovery and development, it could lead to the emergence of substitute products that disrupt Shionogi’s market position, especially if these alternatives prove to be more effective or safer.
2. Disintermediation: With advancements in AI, direct-to-consumer health solutions powered by technology might reduce the reliance on traditional pharmaceutical companies. Patients may turn to AI-driven platforms for diagnoses, treatment recommendations, and even prescriptions. If these trends continue, Shionogi could face challenges in maintaining its traditional distribution channels and relationships with healthcare providers.
3. Margin pressure: AI can optimize various aspects of the pharmaceutical value chain, from research and development to marketing and sales. If competitors leverage AI to improve efficiency and reduce costs, it could intensify price competition in the industry. This might pressure Shionogi’s profit margins, especially if it does not adopt similar technologies or if its operational costs remain higher.
In conclusion, while AI presents material threats through substitution, disintermediation, and margin pressure, it also offers opportunities for Shionogi to innovate and enhance its offerings. How the company navigates these challenges will significantly influence its future competitive positioning.

The sensitivity of Shionogi’s earnings, cash flow, and valuation to changes in interest rates can be assessed from several perspectives.
First, interest rates can impact the company’s cost of capital. If interest rates rise, borrowing costs increase, potentially affecting Shionogi’s ability to finance its operations and investments affordably. Higher interest rates can also lead to a reevaluation of the company’s valuation metrics, as discounted cash flow models may yield lower present values due to higher discount rates.
Second, changes in interest rates influence the broader economic environment, which can affect demand for pharmaceutical products. For instance, during periods of increasing rates, consumer behavior may shift towards more cautious spending, impacting prescription volumes and ultimately sales.
Third, the strength of the currency in which Shionogi operates can also react to interest rate changes, particularly if the company has international operations or revenue streams. Currency fluctuations can influence profit margins and repatriation of earnings.
Lastly, a company’s earnings and cash flow from operations are also tied to its ability to access capital for research and development purposes. Increased interest rates can slow down innovation and new product development if the costs associated with financing rise.
In summary, Shionogi’s financial metrics are sensitive to changes in interest rates through the mechanisms of borrowing costs, economic demand influences, currency fluctuations, and capital access for ongoing operations and developmental initiatives.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvdT M1Y0FSQ2tK M1dNOXB1cn dVZGgud2Vi cCIgYWx0PS JTaGlvbm9n aSIgdGl0bG U9IlNoaW9u b2dpIiAgY2 xhc3M9Imlt Zy1mbHVpZC IgaGVpZ2h0 PTkwIHdpZH RoPTkwIGxv YWRpbmc9J2 xhenknIHN0 eWxlPSdib3 JkZXItcmFk aXVzOiA2cH g7Jz4KCiAg ICAgICAgIC AgICAgICAg ICAgPGRpdi BzdHlsZT0n ZmxleDogMT sgdGV4dC1h bGlnbjogY2 VudGVyOyBt YXJnaW4tbG VmdDogNXB4 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxw IHN0eWxlPS dmb250LXNp emU6IDI2cH g7IGNvbG9y OiAjMzMzOy BtYXJnaW4t Ym90dG9tOi AxNXB4Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICDw n5OIIFdhbn QgdG8gcmVh ZCBtb3JlIG Fib3V0IFNo aW9ub2dpPw ogICAgICAg ICAgICAgIC AgICAgICAg ICA8L3A+Cg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdpbmRl eC5waHA/cG FnZT1zaWdu dXAnIHN0eW xlPScKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICMw MDdCRkY7Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBjb2 xvcjogI2Zm ZjsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHBhZGRpbm c6IDEwcHgg MjBweDsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJvcm Rlci1yYWRp dXM6IDVweD sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH RleHQtZGVj b3JhdGlvbj ogbm9uZTsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGZv bnQtd2VpZ2 h0OiBib2xk OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luLX JpZ2h0OiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdHJhbn NpdGlvbjog YmFja2dyb3 VuZC1jb2xv ciAwLjNzIG Vhc2U7Jwog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgb25t b3VzZW92ZX I9J3RoaXMu c3R5bGUuYm Fja2dyb3Vu ZENvbG9yPS IjMDA1NmIz IicKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IG9ubW91c2 VvdXQ9J3Ro aXMuc3R5bG UuYmFja2dy b3VuZENvbG 9yPSIjMDA3 QkZGIic+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBTaW duIHVwIGZv ciBmcmVlCi AgICAgICAg ICAgICAgIC AgICAgICAg IDwvYT4KCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxzcGFuIH N0eWxlPSdt YXJnaW46ID AgOHB4OyBj b2xvcjogIz U1NTsnPm9y PC9zcGFuPg oKICAgICAg ICAgICAgIC AgICAgICAg ICAgPGEgaH JlZj0naW5k ZXgucGhwP3 BhZ2U9bG9n aW4nIHN0eW xlPScKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGNvbG9y OiAjMDA3Qk ZGOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdGV4dC1k ZWNvcmF0aW 9uOiB1bmRl cmxpbmU7Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBmb2 50LXdlaWdo dDogNTAwOy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Bsb2cgaW4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9hPgoK CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxwIHN0 eWxlPSdtYX JnaW4tdG9w OiAxNXB4Oy Bmb250LXNp emU6IDEzcH g7IGZvbnQt d2VpZ2h0Oi Bib2xkOyBj b2xvcjogI2 QzMmYyZjsn PgogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg 8J+UkyBVbm xvY2sgb3Vy IGZyZWUgZ3 VpZGU6IDxp PiJUaGUgQ2 hlY2tsaXN0 IFZhbHVlIE ludmVzdG9y IOKAlCBBIF NtYXJ0ZXIg V2F5IHRvIF BpY2sgU3Rv Y2tzIjwvaT 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9wPg oKICAgICAg ICAgICAgIC AgICAgICAg ICAgPCEtLQ ogICAgICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdt YXJnaW4tdG 9wOiAxMnB4 OyBmb250LX NpemU6IDEz cHg7IGNvbG 9yOiAjNDQ0 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBTaWduIH VwIG5vdyBh bmQgZ2V0IG 91ciBmcmVl IGVCb29rIA ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgPG I+VGhlIENo ZWNrbGlzdC BWYWx1ZSBJ bnZlc3Rvci DigJQgQSBT bWFydGVyIF dheSB0byBQ aWNrIFN0b2 NrczwvYj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIC0tPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8IS0tCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xkaXYgc3R5 bGU9J21hcm dpbi10b3A6 IDE2cHg7IG ZvbnQtc2l6 ZTogMTRweD sgY29sb3I6 ICM0NDQ7IG ZvbnQtZmFt aWx5OiAtYX BwbGUtc3lz dGVtLCBCbG lua01hY1N5 c3RlbUZvbn QsIFNlZ29l IFVJLCBSb2 JvdG8sIEhl bHZldGljYS BOZXVlLCBz YW5zLXNlcm lmOyBsaW5l LWhlaWdodD ogMS42Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBI YXZlIHlvdS BoZWFyZCBh Ym91dCBvdX Igc2hvcnQg PHN0cm9uZy BzdHlsZT0n Zm9udC13ZW lnaHQ6IDYw MDsnPkRhaW x5IFZpZGVv IE5ld3NsZX R0ZXI8L3N0 cm9uZz4/Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8YS BocmVmPSdo dHRwczovL3 d3dy5pbnNp Z2h0ZnVsdm FsdWUuY29t L25ld3NsZX R0ZXIucGhw JyB0YXJnZX Q9J19ibGFu aycgc3R5bG U9J2NvbG9y OiAjMDA3Qk ZGOyB0ZXh0 LWRlY29yYX Rpb246IG5v bmU7IGZvbn Qtd2VpZ2h0 OiA1MDA7IG 1hcmdpbi1s ZWZ0OiA2cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBG aW5kIG91dC Btb3JlCiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8L2E+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICAg ICAgICAgIC AgICAtLT4K ICAgICAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgICAgIDwv ZGl2PgogIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgCi AgICAgICAg CiAgICAgIC AgPHNwYW4g Y2xhc3M9J2 JsdXJyZWQt dGV4dCc+Ci AgICAgICAg ICAgIExTQl RhR2x2Ym0g OW5hU0FtSU VOdiBMaXdn VEhSa0xpIE JwY3lCaElF cGggY0dGdV pYTmxJSCBC b1lYSnRZV0 5sIGRYUnBZ MkZzSUcgTn ZiWEJoYm5r ZyBabTkxYm 1SbFpDIEJw YmlBeE9EYz QgSUdKNUlF ZHBjMiBGaW RYSnZJRk5v IGFXOXVieU JwYmkgQlBj MkZyWVN3Zy BTbUZ3WVc0 dUlEIHhpY2 o0dElGUm8g WlNCamIyMX dZVyA1NTRv Q1pjeUJ1IF lXMWxJR052 YlcgVnpJR1 p5YjIwZyBk R2hsSUdadm RXIDVrWlhM aWdKbHogSU d4aGMzUWdi bSBGdFpTd2 dVMmhwIGIy NXZMQ0JoYm 0gUWdkR2hs SUVwaCBjR0 Z1WlhObElI IGR2Y21RZ1 oya3MgSUcx bFlXNXBibS BjZ2MyTnBa VzVqIFpTNG dQR0p5UGkg MGdVMmhwYj I1diBaMmtn YVhNZ2RHIG hsSUhObFky OXUgWkMxdm JHUmxjMyBR Z1NtRndZVz VsIGMyVWdj R2hoY20gMW hZMlYxZEds aiBZV3dnWT I5dGNHIEZ1 ZVN3Z1lXWj AgWlhJZ1ZH RnJaVyBSaE lGQm9ZWEp0 IFlXTmxkWF JwWTIgRnNj eTRnUEdKeS BQaTBnVkdo bElHIE52Yl hCaGJubmkg Z0pseklHTj FjbiBKbGJu UWdhR1ZoIF pIRjFZWEow WlggSnpJR2 x6SUd4diBZ MkYwWldRZ2 FXIDRnVDNO aGEyRXMgSU hkcGRHZ2dZ VyBSa2FYUn BiMjVoIGJD QnZabVpwWT IgVnpJR0Z1 WkNCeSBaWE 5sWVhKamFD IEJtWVdOcG JHbDAgYVdW eklHbHVJRy A5MGFHVnlJ R05wIGRHbG xjeUJwYmkg QktZWEJoYm l3ZyBZWE1n ZDJWc2JDIE JoY3lCcGJp QjAgYUdVZ1 ZXNXBkRyBW a0lGTjBZWF JsIGN5d2dR MmhwYm0gRX NJR0Z1WkNC RiBkWEp2Y0 dVdUlEIHhp Y2o0dElGTm 8gYVc5dWIy ZHBJRyBoaG N5QmhJR1Jw IGRtVnljMl VnY0cgOXlk R1p2Ykdsdi BJRzltSUdS eWRXIGR6TE NCcGJtTnMg ZFdScGJtY2 dkSCBKbFlY UnRaVzUwIG N5Qm1iM0ln YVcgNW1aV0 4wYVc5MSBj eUJrYVhObF lYIE5sY3l3 Z1kyRnkgWk dsdmRtRnpZ MyBWc1lYSW daR2x6IGIz SmtaWEp6TE MgQmhibVFn WTJGdSBZMl Z5TGlBOFlu IEkrTFNCVW FHVWcgWTI5 dGNHRnVlUy BCcGN5QnJi bTkzIGJpQm 1iM0lnWkcg VjJaV3h2Y0 dsdSBaeUJw Ym01dmRtIE YwYVhabElH UnkgZFdkek xDQmxjMyBC bFkybGhiR3 g1IElHbHVJ SFJvWlMgQm hjbVZoY3lC diBaaUJoYm 5ScExXIGx1 Wm1WamRHbD IgWlhNZ1lX NWtJSCBCaG FXNGdiV0Z1 IFlXZGxiV1 Z1ZEMgNGdQ R0p5UGkwZy BTVzRnTWpB eE9DIHdnVT JocGIyNXYg WjJrZ2NHRn lkRyA1bGNt VmtJSGRwIG RHZ2dSMmxz WlcgRmtJRk 5qYVdWdSBZ MlZ6SUhSdk lHIFJsZG1W c2IzQWcgWV c1a0lHTnZi VyAxbGNtTn BZV3hwIGVt VWdZU0J1Wl ggY2dTRWxX SUhSeSBaV0 YwYldWdWRD IDRnUEdKeV BpMGcgVTJo cGIyNXZaMi BrZ2FHRnpJ R0VnIGMzUn liMjVuSUcg TnZiVzFwZE cxbCBiblFn ZEc4Z2MzIF Z6ZEdGcGJt RmkgYVd4cG RIa2dZVyA1 a0lHaGhjeU J5IFpXTmxh WFpsWkMgQn laV052WjI1 cCBkR2x2Ym lCbWIzIEln YVhSeklHVn UgZG1seWIy NXRaVyA1MF lXd2dZVzVr IElITnZZMm xoYkMgQnla WE53YjI1ei BhV0pwYkds MGVTIEJsWm 1admNuUnog TGlBOFluSS tMUyBCVWFH VWdZMjl0IG NHRnVlU0Jo YkggTnZJR2 x1ZG1WeiBk SE1nYUdWaG RtIGxzZVNC cGJpQnkgWl hObFlYSmph QyBCaGJtUW daR1YyIFpX eHZjRzFsYm 4gUXNJSGRw ZEdnZyBZWE J3Y205NGFX IDFoZEdWc2 VTQXkgTlNV Z2IyWWdhWC BSeklISmxk bVZ1IGRXVn pJR0ZzYkcg OWpZWFJsWk NCMCBieUJT SmtRdUlEIH hpY2o0dElF bHUgSURJd0 1qRXNJRiBO b2FXOXViMm RwIElHRnVi bTkxYm0gTm xaQ0IwYUdG MCBJR2wwY3 lCbWJIIFVn ZEhKbFlYUn QgWlc1MExD QlliMiBac2 RYcGhMQ0Jv IFlXUWdjbV ZqWlcgbDJa V1FnZEdobC BJR1pwY25O MElHIGRzYj JKaGJDQmgg Y0hCeWIzWm hiQyBCbWIz SWdiM1psIG NpMTBhR1V0 WTIgOTFibl JsY2lCMSBj MlV1SUVsME lHIGx6SUhS b1pTQm0gYV hKemRDQndj bSBWelkzSn BjSFJwIGIy NHRkRzh0VD EgUkRJSE4z YVhSaiBhQ0 JtYjNJZ1lT IEJtYkhVZ2 RISmwgWVhS dFpXNTBJRy BsdUlFcGhj R0Z1IExnPT 0KICAgICAg ICA8L3NwYW 4+CiAgICAg ICAgCiAgIC AgICAg